

Roberto Agresti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9431459/publications.pdf>

Version: 2024-02-01

74
papers

3,211
citations

212478

28
h-index

169272

56
g-index

77
all docs

77
docs citations

77
times ranked

4749
citing authors

#	ARTICLE	IF	CITATIONS
1	Decoding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation. <i>Cancers</i> , 2019, 11, 911.	1.7	40
2	Wound Healing Fluid Reflects the Inflammatory Nature and Aggressiveness of Breast Tumors. <i>Cells</i> , 2019, 8, 181.	1.8	19
3	Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients. <i>BMC Cancer</i> , 2018, 18, 651.	1.1	16
4	The PDGFR ² /ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer. <i>BMC Cancer</i> , 2018, 18, 586.	1.1	16
5	Partial breast irradiation with CyberKnife after breast conserving surgery: a pilot study in early breast cancer. <i>Radiation Oncology</i> , 2018, 13, 49.	1.2	28
6	Dynamics of the hazard for distant metastases after ipsilateral breast tumor recurrence according to estrogen receptor status: An analysis of 2851 patients. <i>Breast</i> , 2018, 40, 131-135.	0.9	3
7	Evaluation of Local Oncologic Safety in Nipple-Areola Complex-sparing Mastectomy After Primary Chemotherapy: A Propensity Score-matched Study. <i>Clinical Breast Cancer</i> , 2017, 17, 219-231.	1.1	28
8	Sentinel node biopsy after primary chemotherapy in cT2 N0/1 breast cancer patients: Long-term results of a retrospective study. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2012-2020.	0.5	20
9	Ten-year results of applying an original scoring system for addressing adjuvant therapy use after breast-conserving surgery for ductal carcinoma in situ of the breast. <i>Breast</i> , 2017, 35, 63-68.	0.9	5
10	Neoadjuvant Chemotherapy Exerts Selection Pressure Towards Luminal Phenotype Breast Cancer. <i>Breast Care</i> , 2017, 12, 391-394.	0.8	9
11	CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers. <i>Oncotarget</i> , 2016, 7, 69649-69665.	0.8	29
12	Association of adiposity, dysmetabolisms, and inflammation with aggressive breast cancer subtypes: a cross-sectional study. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 179-189.	1.1	34
13	Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy. <i>Breast</i> , 2016, 29, 90-95.	0.9	31
14	Time trends in axilla management among early breast cancer patients: Persisting major variation in clinical practice across European centers. <i>Acta Oncologica</i> , 2016, 55, 712-719.	0.8	20
15	Out-of-pocket costs for cancer survivors between 5 and 10 years from diagnosis: an Italian population-based study. <i>Supportive Care in Cancer</i> , 2016, 24, 2225-2233.	1.0	17
16	Secondary electrospray ionization-mass spectrometry and a novel statistical bioinformatic approach identifies a cancer-related profile in exhaled breath of breast cancer patients: a pilot study. <i>Journal of Breath Research</i> , 2015, 9, 031001.	1.5	25
17	A Breast Cancer Clinical Registry in An Italian Comprehensive Cancer Center: An Instrument for Descriptive, Clinical, and Experimental Research. <i>Tumori</i> , 2015, 101, 440-446.	0.6	10
18	Androgen Receptor CAG Repeat Length and Estrogen Receptor Status in Postmenopausal Breast Cancer Prognosis. <i>International Journal of Biological Markers</i> , 2015, 30, 418-424.	0.7	3

#	ARTICLE	IF	CITATIONS
19	Omission of radiotherapy in elderly patients with early breast cancer: 15-Year results of a prospective non-randomised trial. <i>European Journal of Cancer</i> , 2015, 51, 1358-1364.	1.3	21
20	¹⁸ F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 818-830.	3.3	34
21	Electrochemotherapy in the Treatment of Cutaneous Metastases from Breast Cancer: A Multicenter Cohort Analysis. <i>Annals of Surgical Oncology</i> , 2015, 22, 442-450.	0.7	58
22	Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study. <i>European Journal of Cancer</i> , 2015, 51, 2191-2205.	1.3	205
23	Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: A randomized clinical trial (INT09/98). <i>Cancer</i> , 2014, 120, 885-893.	2.0	68
24	Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: Results and clinical implications after eight-years follow-up. <i>Breast</i> , 2014, 23, 334-340.	0.9	1
25	Axillary dissection versus no axillary dissection in older T1N0 breast cancer patients: 15-Year results of trial and out-trial patients. <i>European Journal of Surgical Oncology</i> , 2014, 40, 805-812.	0.5	37
26	Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. <i>Annals of Oncology</i> , 2014, 25, 352-357.	0.6	53
27	Reply to what if axillary lymph node dissection became less fashionable?. <i>Cancer</i> , 2014, 120, 2535-2536.	2.0	0
28	Subtype-dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer. <i>Molecular Oncology</i> , 2014, 8, 1278-1289.	2.1	39
29	PDGFR ² and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells. <i>Molecular Oncology</i> , 2014, 8, 968-981.	2.1	37
30	Ex Vivo MRI Evaluation of Breast Tumors: A Novel Tool for Verifying Resection of Nonpalpable Only MRI Detected Lesions. <i>Breast Journal</i> , 2013, 19, 659-663.	0.4	12
31	Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma In Situ: 15-Year Recurrence Rates and Outcome After a Recurrence, From the EORTC 10853 Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4054-4059.	0.8	301
32	Cell Proliferation of the Primary Tumor Predicts Ipsilateral Axillary Node Disease in Elderly Breast Cancer Patients. <i>International Journal of Biological Markers</i> , 2013, 28, 24-31.	0.7	0
33	Is the risk of primary hyperparathyroidism increased in patients with untreated breast cancer?. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 321-5.	1.8	2
34	Significance of ipsilateral breast tumor recurrence after breast conserving treatment: role of surgical removal. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2013, 25, 22-31.	0.7	6
35	Axillary Dissection Versus No Axillary Dissection in Older Patients With T1N0 Breast Cancer. <i>Annals of Surgery</i> , 2012, 256, 920-924.	2.1	114
36	What is specific in hereditary breast cancer? High T2 signal intensity as a new semeiotic pattern?. <i>European Journal of Radiology</i> , 2012, 81, S165-S170.	1.2	1

#	ARTICLE	IF	CITATIONS
37	Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers. BMC Cancer, 2012, 12, 599.	1.1	16
38	Circulating Sex Hormones and Tumor Characteristics in Postmenopausal Breast Cancer Patients. A Cross-Sectional Study. International Journal of Biological Markers, 2011, 26, 241-246.	0.7	8
39	Axillary Dissection Versus No Axillary Dissection in Elderly Patients with Breast Cancer and No Palpable Axillary Nodes: Results After 15 Years of Follow-Up. Annals of Surgical Oncology, 2011, 18, 125-133.	0.7	141
40	Recurrence and mortality according to Estrogen Receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast. BMC Cancer, 2010, 10, 656.	1.1	34
41	Is there a Specific Magnetic Resonance Phenotype Characteristic of Hereditary Breast Cancer?. Tumori, 2010, 96, 363-384.	0.6	2
42	The Role of FDG-PET for Axillary Lymph Node Staging in Primary Breast Cancer. , 2008, , 157-167.		0
43	Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness. European Journal of Cancer, 2006, 42, 1057-1061.	1.3	8
44	FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncology Reports, 2005, 14, 415.	1.2	25
45	Immunological and pathobiological roles of fibulin-1 in breast cancer. Oncogene, 2004, 23, 2153-2160.	2.6	45
46	FDG-PET for axillary lymph node staging in primary breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, S97-S102.	3.3	62
47	Absence of interference of serum IgGs from patients with breast cancer and thyroid autoimmunity on the function of human iodide symporter gene stably transfected in CHO cells. Journal of Endocrinological Investigation, 2004, 27, 862-865.	1.8	7
48	Role of HER2 in wound-induced breast carcinoma proliferation. Lancet, The, 2003, 362, 527-533.	6.3	152
49	HER2 and proliferation of wound-induced breast carcinoma. Lancet, The, 2003, 362, 1503.	6.3	4
50	HER2 and proliferation of wound-induced breast carcinoma. Lancet, The, 2003, 362, 1503.	6.3	4
51	Identification of Breast Cancer-Restricted Antigens by Antibody Screening of SKBR3 cDNA Library Using a Preselected Patient's Serum. Breast Cancer Research and Treatment, 2002, 73, 245-256.	1.1	59
52	Letter to the editor. Breast Cancer Research and Treatment, 2001, 70, 155-156.	1.1	10
53	Axillary Lymph Node Staging in Breast Cancer by 2-Fluoro-2-deoxy-D-glucose-Positron Emission Tomography: Clinical Evaluation and Alternative Management. Journal of the National Cancer Institute, 2001, 93, 630-635.	3.0	153
54	HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Annals of Oncology, 2001, 12, S15-S19.	0.6	112

#	ARTICLE	IF	CITATIONS
55	HER2 as a Prognostic Factor in Breast Cancer. <i>Oncology</i> , 2001, 61, 67-72.	0.9	216
56	Breast Cancer Patients Treated Without Axillary Surgery. <i>Annals of Surgery</i> , 2000, 232, 1-7.	2.1	126
57	Impact of nodal status on indication for adjuvant treatment in clinically node negative breast cancer. <i>Annals of Oncology</i> , 2000, 11, 1137-1140.	0.6	10
58	Expression of protein tyrosine phosphatase alpha (RPTP α) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo. <i>Oncogene</i> , 2000, 19, 4979-4987.	2.6	77
59	Fluctuation of HER2 Expression in Breast Carcinomas during the Menstrual Cycle. <i>American Journal of Pathology</i> , 1999, 155, 1543-1547.	1.9	24
60	Association between [18 F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 1429-1434.	3.3	161
61	Proliferation of breast carcinoma during menstrual phases. <i>Lancet, The</i> , 1998, 352, 148-149.	6.3	16
62	Breast cancer staging using technetium-99m sestamibi and indium-111 pentetreotide single-photon emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 192-196.	2.2	25
63	Radiopharmaceuticals for Breast Cancer Imaging. <i>Tumori</i> , 1997, 83, 512-514.	0.6	3
64	Radionuclide imaging of unexpected multifocal breast cancer: surgical implications. <i>Breast</i> , 1997, 6, 386-387.	0.9	2
65	Conservation Surgery After Primary Chemotherapy in Large Carcinomas of the Breast. <i>Annals of Surgery</i> , 1995, 222, 612-618.	2.1	142
66	The influence of radiotherapy on cosmetic outcome after breast conservative surgery. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 33, 59-64.	0.4	37
67	Conservative treatment of breast cancer: Milan experience. <i>Acta Chirurgica Austriaca</i> , 1995, 27, 238-242.	0.2	1
68	Quadrantectomy is not a disfiguring operation for small breast cancer. <i>Breast</i> , 1994, 3, 3-7.	0.9	8
69	Juvenile Classic Kaposi'S Sarcoma: A Report Of Two Cases, One With Family History. <i>Pediatric Hematology and Oncology</i> , 1994, 11, 409-416.	0.3	10
70	Classic Kaposi's Sarcoma: A Review of 90 Cases. <i>Journal of Dermatology</i> , 1992, 19, 548-552.	0.6	19
71	Quantitative and qualitative cosmetic evaluation after conservative treatment for breast cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 1395-1400.	0.9	125
72	Histopathological Characterization of a Novel Monoclonal Antibody, MLC1, Reacting with Lung Carcinomas. <i>Tumori</i> , 1988, 74, 401-410.	0.6	9

#	ARTICLE	IF	CITATIONS
73	Monoclonal Antibodies MBr1 and MBr8 as Predictors of Response to Oophorectomy in Advanced Breast Cancer. Tumori, 1988, 74, 309-312.	0.6	3
74	Characterization of the Specificity by Immunohistology of a Monoclonal Antibody to a Novel Epithelial Antigen of Ovarian Carcinomas. Pathology Research and Practice, 1985, 180, 169-180.	1.0	9